Moleculin Biotech, Inc. MBRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.79% | 2.97% | 3.82% | -0.10% | -4.78% |
| Depreciation & Amortization | -62.30% | -46.40% | -28.57% | -13.85% | -6.87% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.49% | 4.35% | -5.78% | -16.27% | -8.25% |
| Operating Income | -13.49% | -4.35% | 5.78% | 16.27% | 8.25% |
| Income Before Tax | 18.74% | -50.10% | -28.84% | -87.32% | -31.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.74% | -50.10% | -28.84% | -87.32% | -31.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.74% | -50.10% | -28.84% | -87.32% | -31.79% |
| EBIT | -13.49% | -4.35% | 5.78% | 16.27% | 8.25% |
| EBITDA | -13.86% | -4.59% | 5.67% | 16.28% | 8.26% |
| EPS Basic | 80.47% | 12.63% | -67.13% | -- | -- |
| Normalized Basic EPS | 81.16% | 13.61% | -66.99% | -- | -- |
| EPS Diluted | 80.47% | 12.63% | -67.13% | -- | -- |
| Normalized Diluted EPS | 81.16% | 13.61% | -66.99% | -- | -- |
| Average Basic Shares Outstanding | 1,029.72% | 1,371.53% | 2,239.60% | -- | -- |
| Average Diluted Shares Outstanding | 1,029.72% | 1,371.53% | 2,239.60% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |